SAN DIEGO (AP) — SAN DIEGO (AP) — Regulus Therapeutics Inc. (RGLS) on Thursday reported a loss of $12.8 million in its fourth quarter. On a per-share basis, the San Diego-based company said it ...
In December 2024, Regulus met with the FDA for an End-of-Phase 1 meeting where they reached alignment on the acceptability of the program's CMC, non-clinical and clinical pharmacology plans and ...
SAN DIEGO, March 4, 2025 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback